S&P 500   3,858.79 (+0.18%)
DOW   31,219.76 (+0.10%)
QQQ   326.65 (+0.89%)
AAPL   136.94 (+3.72%)
MSFT   225.91 (+0.70%)
FB   273.09 (+2.10%)
GOOGL   1,891.00 (+0.58%)
AMZN   3,322.02 (+1.80%)
TSLA   846.76 (-0.43%)
NVDA   548.42 (+2.58%)
BABA   259.96 (-2.08%)
CGC   33.77 (+0.42%)
GE   11.11 (-2.46%)
MU   83.96 (+0.55%)
AMD   91.66 (+3.28%)
NIO   58.39 (+1.18%)
T   28.89 (-0.24%)
F   11.54 (+6.26%)
ACB   11.20 (-2.95%)
BA   207.41 (-1.91%)
DIS   171.92 (-0.99%)
NFLX   579.83 (-1.11%)
GILD   67.05 (-1.38%)
S&P 500   3,858.79 (+0.18%)
DOW   31,219.76 (+0.10%)
QQQ   326.65 (+0.89%)
AAPL   136.94 (+3.72%)
MSFT   225.91 (+0.70%)
FB   273.09 (+2.10%)
GOOGL   1,891.00 (+0.58%)
AMZN   3,322.02 (+1.80%)
TSLA   846.76 (-0.43%)
NVDA   548.42 (+2.58%)
BABA   259.96 (-2.08%)
CGC   33.77 (+0.42%)
GE   11.11 (-2.46%)
MU   83.96 (+0.55%)
AMD   91.66 (+3.28%)
NIO   58.39 (+1.18%)
T   28.89 (-0.24%)
F   11.54 (+6.26%)
ACB   11.20 (-2.95%)
BA   207.41 (-1.91%)
DIS   171.92 (-0.99%)
NFLX   579.83 (-1.11%)
GILD   67.05 (-1.38%)
S&P 500   3,858.79 (+0.18%)
DOW   31,219.76 (+0.10%)
QQQ   326.65 (+0.89%)
AAPL   136.94 (+3.72%)
MSFT   225.91 (+0.70%)
FB   273.09 (+2.10%)
GOOGL   1,891.00 (+0.58%)
AMZN   3,322.02 (+1.80%)
TSLA   846.76 (-0.43%)
NVDA   548.42 (+2.58%)
BABA   259.96 (-2.08%)
CGC   33.77 (+0.42%)
GE   11.11 (-2.46%)
MU   83.96 (+0.55%)
AMD   91.66 (+3.28%)
NIO   58.39 (+1.18%)
T   28.89 (-0.24%)
F   11.54 (+6.26%)
ACB   11.20 (-2.95%)
BA   207.41 (-1.91%)
DIS   171.92 (-0.99%)
NFLX   579.83 (-1.11%)
GILD   67.05 (-1.38%)
S&P 500   3,858.79 (+0.18%)
DOW   31,219.76 (+0.10%)
QQQ   326.65 (+0.89%)
AAPL   136.94 (+3.72%)
MSFT   225.91 (+0.70%)
FB   273.09 (+2.10%)
GOOGL   1,891.00 (+0.58%)
AMZN   3,322.02 (+1.80%)
TSLA   846.76 (-0.43%)
NVDA   548.42 (+2.58%)
BABA   259.96 (-2.08%)
CGC   33.77 (+0.42%)
GE   11.11 (-2.46%)
MU   83.96 (+0.55%)
AMD   91.66 (+3.28%)
NIO   58.39 (+1.18%)
T   28.89 (-0.24%)
F   11.54 (+6.26%)
ACB   11.20 (-2.95%)
BA   207.41 (-1.91%)
DIS   171.92 (-0.99%)
NFLX   579.83 (-1.11%)
GILD   67.05 (-1.38%)
Log in
NASDAQ:RDNT

RadNet Stock Forecast, Price & News

$20.03
-0.23 (-1.14 %)
(As of 01/21/2021 03:15 PM ET)
Add
Compare
Today's Range
$19.75
Now: $20.03
$20.19
50-Day Range
$17.91
MA: $19.40
$21.10
52-Week Range
$5.81
Now: $20.03
$23.45
Volume8,042 shs
Average Volume196,857 shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52
RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. It offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. The company was founded by Howard G. Berger in 1985 and is headquartered in Los Angeles, CA.
RadNet logo

MarketRank

Overall MarketRank

1.48 out of 5 stars

Medical Sector

447th out of 1,926 stocks

Medical Laboratories Industry

8th out of 39 stocks

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone(310) 478-7808
Employees8,498

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.15 billion
Cash Flow$3.14 per share
Book Value$4.63 per share

Profitability

Net Income$14.76 million

Miscellaneous

Market Cap$1.03 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$20.03
-0.23 (-1.14 %)
(As of 01/21/2021 03:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











RadNet (NASDAQ:RDNT) Frequently Asked Questions

How has RadNet's stock price been impacted by Coronavirus?

RadNet's stock was trading at $17.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RDNT shares have increased by 16.3% and is now trading at $20.03.
View which stocks have been most impacted by COVID-19
.

Is RadNet a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RadNet stock.
View analyst ratings for RadNet
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than RadNet?

Wall Street analysts have given RadNet a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but RadNet wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as RadNet's CEO?

1,448 employees have rated RadNet CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among RadNet's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for RadNet
.

How were RadNet's earnings last quarter?

RadNet, Inc. (NASDAQ:RDNT) released its quarterly earnings results on Monday, November, 9th. The medical research company reported $0.15 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.21. The medical research company earned $291.80 million during the quarter, compared to analysts' expectations of $254.68 million. RadNet had a negative net margin of 0.98% and a negative return on equity of 2.72%. RadNet's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the business earned $0.08 EPS.
View RadNet's earnings history
.

What price target have analysts set for RDNT?

2 brokerages have issued 1-year price targets for RadNet's stock. Their forecasts range from $22.00 to $23.00. On average, they anticipate RadNet's share price to reach $22.50 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts' price targets for RadNet
or view Wall Street analyst' top-rated stocks.

Are investors shorting RadNet?

RadNet saw a drop in short interest in December. As of December 31st, there was short interest totaling 806,900 shares, a drop of 18.5% from the December 15th total of 989,700 shares. Based on an average daily volume of 208,000 shares, the days-to-cover ratio is currently 3.9 days. Approximately 1.9% of the company's stock are sold short.
View RadNet's Short Interest
.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), The Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Howard G. Berger, Chairman, Co-President & Chief Executive Officer
  • Norman R. Hames, Co-President & COO-Western Operations
  • Stephen M. Forthuber, Co-President & COO-Eastern Operations
  • Mark D. Stolper, Chief Financial Officer & Executive VP
  • John V. Crues, Secretary, Director, VP & Medical Director

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Dalton Greiner Hartman Maher & Co. (0.72%), Miracle Mile Advisors LLC (0.10%) and State of Alaska Department of Revenue (0.06%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, David L Swartz, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames.
View institutional ownership trends for RadNet
.

Which major investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., and State of Alaska Department of Revenue.
View insider buying and selling activity for RadNet
or view top insider-selling stocks.

Which major investors are buying RadNet stock?

RDNT stock was purchased by a variety of institutional investors in the last quarter, including Miracle Mile Advisors LLC.
View insider buying and selling activity for RadNet
or or view top insider-buying stocks.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $20.03.

How big of a company is RadNet?

RadNet has a market capitalization of $1.03 billion and generates $1.15 billion in revenue each year. The medical research company earns $14.76 million in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 8,498 workers across the globe.

What is RadNet's official website?

The official website for RadNet is www.radnet.com.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at (310) 478-7808 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.